X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3323) 3323
Publication (364) 364
Newsletter (134) 134
Book Review (60) 60
Newspaper Article (24) 24
Book Chapter (16) 16
Magazine Article (11) 11
Conference Proceeding (7) 7
Dissertation (4) 4
Trade Publication Article (2) 2
Transcript (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1728) 1728
fingolimod (1624) 1624
humans (1602) 1602
multiple sclerosis (1432) 1432
sphingosine - analogs & derivatives (1373) 1373
fingolimod hydrochloride (1322) 1322
animals (1176) 1176
fty720 (920) 920
male (832) 832
clinical neurology (765) 765
female (762) 762
immunosuppressive agents - therapeutic use (732) 732
propylene glycols - pharmacology (668) 668
oral fingolimod (643) 643
mice (610) 610
immunosuppressive agents - pharmacology (563) 563
propylene glycols - therapeutic use (551) 551
sphingosine - pharmacology (534) 534
neurosciences (525) 525
multiple sclerosis - drug therapy (473) 473
immunology (463) 463
adult (459) 459
pharmacology & pharmacy (451) 451
sphingosine - therapeutic use (418) 418
rats (409) 409
sphingosine 1-phosphate (391) 391
natalizumab (386) 386
multiple sclerosis, relapsing-remitting - drug therapy (381) 381
sphingosine-1-phosphate (364) 364
middle aged (351) 351
neurology (344) 344
research (339) 339
sphingosine (325) 325
multiple-sclerosis (311) 311
fingolimod hydrochloride - therapeutic use (303) 303
placebo-controlled trial (285) 285
immunosuppressive agents - adverse effects (284) 284
drug therapy (282) 282
receptors, lysosphingolipid - metabolism (276) 276
treatment outcome (273) 273
analysis (270) 270
mice, inbred c57bl (269) 269
transplantation (264) 264
relapsing multiple-sclerosis (253) 253
phosphates (251) 251
care and treatment (245) 245
double-blind (242) 242
immunosuppressive agents - administration & dosage (238) 238
disease models, animal (228) 228
fingolimod hydrochloride - pharmacology (228) 228
inflammation (223) 223
interferon (223) 223
experimental autoimmune encephalomyelitis (217) 217
lymphocytes (217) 217
article (209) 209
propylene glycols - administration & dosage (206) 206
glatiramer acetate (202) 202
surgery (202) 202
apoptosis (200) 200
magnetic resonance imaging (197) 197
therapy (189) 189
sphingosine - metabolism (182) 182
medical research (179) 179
administration, oral (173) 173
sphingosine - administration & dosage (171) 171
central-nervous-system (168) 168
health aspects (168) 168
lymphocyte egress (168) 168
immunosuppressant (167) 167
time factors (166) 166
abridged index medicus (165) 165
propylene glycols - adverse effects (165) 165
dosage and administration (164) 164
safety (164) 164
efficacy (162) 162
activation (159) 159
biochemistry & molecular biology (156) 156
in-vivo (154) 154
t-cells (154) 154
young adult (154) 154
clinical trials (152) 152
lysophospholipids - metabolism (152) 152
expression (151) 151
sphingosine - adverse effects (151) 151
cell biology (148) 148
patients (148) 148
progressive multifocal leukoencephalopathy (147) 147
receptors, lysosphingolipid - agonists (145) 145
dose-response relationship, drug (144) 144
fingolimod hydrochloride - adverse effects (143) 143
immunologic factors - therapeutic use (143) 143
medicine, experimental (138) 138
cells, cultured (137) 137
fingolimod fty720 (137) 137
disease progression (135) 135
apoptosis - drug effects (134) 134
circulating mature lymphocytes (132) 132
phosphorylation (132) 132
cells (128) 128
medicine & public health (128) 128
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3235) 3235
German (70) 70
Spanish (47) 47
Japanese (44) 44
French (36) 36
Chinese (20) 20
Hungarian (13) 13
Russian (11) 11
Portuguese (8) 8
Czech (7) 7
Polish (4) 4
Finnish (3) 3
Turkish (3) 3
Italian (2) 2
Persian (2) 2
Korean (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Circulation, ISSN 0009-7322, 03/2016, Volume 133, Issue 10, pp. 954 - 966
Journal Article
Drugs, ISSN 0012-6667, 10/2017, Volume 77, Issue 16, pp. 1755 - 1768
Since the approval of fingolimod, several selective sphingosine-1-phosphate receptor modulators have entered clinical development for multiple sclerosis.... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | LONG-TERM | BAF312 SIPONIMOD | TUMEFACTIVE MS | ORAL FINGOLIMOD FTY720 | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | OPEN-LABEL | TOXICOLOGY | PLACEBO-CONTROLLED TRIAL | DISEASE-MODIFYING THERAPIES | SAFETY PROFILE | CLINICAL-PRACTICE | Fingolimod Hydrochloride - pharmacology | Multiple Sclerosis - diagnosis | Risk Assessment | Humans | Natalizumab - adverse effects | Natalizumab - chemistry | Natalizumab - pharmacology | Fingolimod Hydrochloride - chemistry | Natalizumab - administration & dosage | Multiple Sclerosis - immunology | Immunosuppressive Agents - adverse effects | Receptors, Lysosphingolipid - metabolism | Fingolimod Hydrochloride - adverse effects | Immunosuppressive Agents - pharmacology | Immunosuppressive Agents - administration & dosage | Immunosuppressive Agents - chemistry | Fingolimod Hydrochloride - administration & dosage | Multiple Sclerosis - drug therapy | Multiple sclerosis | Care and treatment | Usage | Dosage and administration | Fingolimod | Drug therapy | Short term | Phosphates | Washouts | Nervous system | Malignancy | Modulators | Sphingosine 1-phosphate | Cell adhesion & migration | Lymphocytes | Phosphate | Risk assessment | Safety | Patient satisfaction | Heart diseases | Drug dosages | Edema | Lymphatic system | Effectiveness | Immunomodulation | Switching | Studies | Heart rate | Side effects | Titration | Review
Journal Article
NEUROLOGY, ISSN 0028-3878, 03/2019, Volume 92, Issue 10, pp. 451 - 452
Objective: To test blood and CSF neurofilament light chain (NfL) levels in relation to disease progression and survival in amyotrophic lateral sclerosis (ALS).... 
ORAL FINGOLIMOD | CLINICAL NEUROLOGY
Journal Article
Lancet Neurology, The, ISSN 1474-4422, 2014, Volume 13, Issue 6, pp. 545 - 556
Journal Article
BMC Neurology, ISSN 1471-2377, 04/2014, Volume 14, Issue 1, pp. 65 - 65
Journal Article
Journal of Neuroimmunology, ISSN 0165-5728, 2012, Volume 256, Issue 1, pp. 13 - 18
Journal Article